One year of pemafibrate therapy improves hepatic inflammation, function, and fibrosis without changing weight or glycemic control in patients with NAFLD refractory to long-term SGLT2 inhibitor therapy. Here, SLC5A2 is linked to metabolic dysfunction-associated steatotic liver disease.